Predictive markers in breast cancer - the future

被引：24

作者：

Faratian, D. ^{[1
]}

Bartlett, J. ^{[1
]}

机构：

[1] Edinburgh Canc Res Ctr, Endocrine Canc Grp, Edinburgh EH4 2XR, Midlothian, Scotland

来源：

HISTOPATHOLOGY | 2008年 / 52卷 / 01期

关键词：

clinical trial; predictive biomarkers; PTEN; RTK inhibitors; topoisomerase II; trastuzumab;

D O I：

10.1111/j.1365-2559.2007.02896.x

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The published literature is awash with examples of new tissue biomarkers promising to predict responses to therapy in breast cancer patients. However, few, if any, of these progress from the laboratory to the clinic. In this review we discuss some of the reasons for this, illustrating our discussion with a selection of biomarkers which are in development and which may be candidates for clinical application within the next few years (topoisomerase II alpha, epidermal growth factor receptor, AKT, phosphatase and tensin homologue). In particular, we explore how our ever increasing knowledge of molecular and pathway biology is facilitating hypothesis-driven biomarker discovery, and the statistical considerations which need to be addressed in order to validate new candidate biomarkers adequately.

引用

页码：91 / 98

页数：8

共 65 条

[21] The Akt-mTOR tango and its relevance to cancer [J].

Hay, N .

CANCER CELL, 2005, 8 (03) :179-183

[22] Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study [J].

Hirsch, FR ;

Varella-Garcia, M ;

McCoy, J ;

West, H ;

Xavier, AC ;

Gumerlock, P ;

Bunn, PA ;

Franklin, WA ;

Crowley, J ;

Gandara, DR .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :6838-6845

[23] Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines [J].

Hollestelle, Antoinette ;

Elstrodt, Fons ;

Nagel, Jord H. A. ;

Kallemeijn, Wouter W. ;

Schutte, Mieke .

MOLECULAR CANCER RESEARCH, 2007, 5 (02) :195-201

[24]

Jarvinen TAH, 1996, AM J PATHOL, V148, P2073

[25] Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer [J].

Järvinen, TAH ;

Tanner, M ;

Rantanen, V ;

Bärlund, M ;

Borg, Å ;

Grénman, S ;

Isola, J .

AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (03) :839-847

[26]

Johnston SRD, 2003, CLIN CANCER RES, V9, p524S

[27] Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer [J].

Jordan, V. Craig ;

Brodie, Angela M. H. .

STEROIDS, 2007, 72 (01) :7-25

[28] Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression [J].

Kersting, C ;

Kuijper, A ;

Schmidt, H ;

Packeisen, J ;

Liedtke, C ;

Tidow, N ;

Gustmann, C ;

Hinrichs, B ;

Wülfing, L ;

Tio, J ;

Boecker, W ;

van Diest, P ;

Brandt, B ;

Buerger, H .

LABORATORY INVESTIGATION, 2006, 86 (01) :54-61

[29] AKT activation predicts outcome in breast cancer patients treated with tamoxifen [J].

Kirkegaard, T ;

Witton, CJ ;

McGlynn, LM ;

Tovey, SM ;

Dunne, B ;

Lyon, A ;

Bartlett, JMS .

JOURNAL OF PATHOLOGY, 2005, 207 (02) :139-146

[30] Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients [J].

Kirkegaard, Tove ;

McGlynn, Liane M. ;

Campbell, Fiona M. ;

Mueller, Sven ;

Tovey, Sian M. ;

Dunne, Barbara ;

Nielsen, Kirsten V. ;

Cooke, Timothy G. ;

Bartlett, John M. S. .

CLINICAL CANCER RESEARCH, 2007, 13 (05) :1405-1411

← 1 2 3 4 5 6 7 →